



M PHARMACEUTICAL ANNOUNCES OPTION GRANTS

VANCOUVER, B.C., CANADA (July 25, 2016) - **M Pharmaceutical, Inc.** (CSE:MQ, OTCQB: MPHMF, FWB:T3F2), (the "Company" or "M Pharma"), announced it has issued 7,400,000 options pursuant to the Company's incentive stock option plan to officers, directors and consultants. These options are exercisable for 5 years at an exercise price of \$0.08 per share.

About M Pharmaceutical Inc.

Formed in early 2015, **M Pharmaceutical Inc.** is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of **C-103**, a reformulation of orlistate from Chelatexx, LLC, the Company will focus on the development of its **Trimeo** capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

For more information contact:

Investor Relations

Phone: +1 604 428 0511

info@m-pharma.ca

www.m-pharma.ca

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the its biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.